Mycophenolate Mofetil 250 mg Capsules Under Fasting Conditions
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to compare the oral bioavailability of an investigational
formulation of mycophenolate mofetil (MMF) 250 mg capsules to an equivalent dose of the
commercially available reference product, CellCept® (mycophenolate mofetil) 250 mg
administered to healthy subjects following an overnight fast of at least 10 hours.